Thus, GLP-1 RAs are effective at preventing MACE than placebo in T2DM patients with obesity, although further studies are warranted to conclude their superiority to SGLT-2 inhibitors. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.